Hematology | Clinical

BLA for Beti-Cel in B-thalassemia Accepted for Priority Review by FDA

November 23, 2021

The newly accepted FDA approval application for betibeglogene autotemcel is supported by 5 studies of the agent across all ages of patients. Eighty-nine percent of evaluable patients achieved transfusion independence.

The Development of a Platform Designed to Activate NK Cells

November 11, 2021

Jeffrey Miller, MD, discusses the background of the Tri-Specific Killer Engager TRICK platform for the activation of natural killer cells for the treatment of refractory tumors, including those that are hematology-based.